Introduction
Postoperative radiation, either alone or in combination with chemotherapy or biological modifiers (e.g. cetuximab, C225) is a key factor in the treatment of head and neck cancer (HNC). The indications for postoperative radiation treatment (PORT) include locally advanced disease [1] , primary tumor site [2] , involved surgical margin [1,3], perineural invasion [4], lymphatic spread [3] , and extranodal capsular extension [1, 3] . The start of PORT, however, may be delayed in a substantial number of patients for medical or technical reasons. Steel [5] described an exponential model showing that microscopic tumor foci left behind after HNC surgery undergo rapid repopulation. Forty-five days after surgery was estimated to be the doubling time of HNC cells. Therefore, a delay in starting PORT was assumed to lead to a greater tumor burden, risk of hypoxia, and a larger fraction of mutated cells that are considered to be radioresistant.
Later studies on delays in initiating PORT, however, yielded controversial results. Some found that an interval of more than 6 weeks impaired outcome [6-8], whereas others reported that a 6-week delay was not associated with lower survival or decreased local control [9-12,13 • ,14] . Mackillop et al. [15] reported an increase in local recurrence with an increase in delay of PORT, but no effect on overall survival. Most of the delays in these studies were due to perioperative wound complications, poor medical status, need for dental care, or lowpatient compliance. The discrepancies in outcome might have been attributable to the retrospective design of the studies and their small patient samples.
The present review, which focuses on the publications of the last 5 years, was prompted by the sparsity of reports on the effect of delayed PORT and the clinical importance of this issue.
Repopulation biology of postoperative head and neck squamous cell cancer
Most of the information about tumor growth rates in HNC has been recruited from retrospective studies. Mackillop et al. [15] reported a probable tumor doubling time of 5-180 days in patients with tonsillar carcinoma, and Al-Dweri et al. [16 •• ] , using an empirical approach with Monte Carlo simulation, found a doubling time of 19-39 days. The latter authors noted that if the surgery-PORT interval exceeded 50 days, the local control rate decreased by around 5%. The reduction appeared to be almost linear, with a decrease of about 0.09% in local control per day of delay and a corresponding time factor of about 0.11 Gy radiation. They hypothesized that in squamous cell cancer of the head and neck the tumor repopulation is directly linked to the regression in tumor mass caused by the surgery. Specifically, the decrease in mass improves the environment of the surviving cells, offering better supplies of nutrients and oxygen, thereby affecting their kinetics. This leads to a reduction in the spontaneous cell loss factor and results in an increase in cell growth.
Suwinski et al. [12] found that the tumor control probability decreased by approximately 0.17% per day of extension of the time gap between surgery and PORT. Thus, a delay of one day in initiating PORT should be compensated by 0.17 Gy radiation, which corresponds to the average of effective doubling time for clonogenic tumor cells (approximately 12 days).
Wyatt et al. [17] , in a theoretical study, reported that in fast-growing tumors, such as head and neck squamous cell cancer, a delay of 1-2 months may have a significant adverse effect on outcome. In slow-growing tumors, however, such as prostate cancer, a delay of several months does not significantly reduce tumor-control probability. They described four different pretreatment doubling times for HNC: 33, 45, 90, and 120 days. A delay of 1 week in starting PORT in HNC led to a 1% reduction in locoregional control.
Outcome of delayed postoperative radiation treatment by subsite
The studies mentioned above included all subtypes of HNC as a single category, except for that of Suwinski et al. [12] . These authors investigated 868 patients, of whom 702 had laryngeal cancer and the remainder had cancer of the oral cavity, oropharynx, or hypopharynx. They found that in nonlaryngeal HNC, a delay in treatment had a statistically significant influence on treatment outcome. In laryngeal cancer, however, only when the treatment was delayed by more than 90 days was outcome affected. Marshak et al. [13 • ] reached a similar conclusion: the time elapsed before initiation of PORT in cases of advanced laryngeal cancer was not a significant prognostic predictor for local control rate and survival. Unlike Suwinski et al. [12] , however, Bastit et al. [10] , in a retrospective study of fast-growing oropharyngeal and hypopharyngeal cancers, did not find a delay in starting adjuvant PORT to have a significant impact on survival or local control relapse.
Terhaard et al. [18 •• ] analyzed 538 patients treated by PORT for salivary gland cancers, which are generally considered relatively slow growing. They found that the local control was not correlated with the surgeryradiotherapy interval, even when there was a 12-week delay.
Role of nodal involvement in the effect of postoperative radiation treatment delay
In the study of Marshak et al. [13 • ] of patients with laryngeal cancer and delayed PORT, lymphatic spread was the only significant bad prognosticator for both local control and survival on multivariate analysis. Suwinski et al. [12] noted that increased treatment gaps, positive surgical margins, lymphatic spread, and extracapsular extension are significantly related to a decrease in relapse-free survival, and Bastit et al. [10] found that pathologic margins and lymphatic spread were the only parameters influencing local control and survival.
Reducing the influence of postoperative radiation treatment delay
Several methods have been proposed to reduce the effect of PORT delay based on shortening overall treatment time (OTT). The treatment package time is defined as the period beginning on the day of operation and terminating with the completion of PORT. Ang et al. [19] , in prospective study, analyzed the outcome of patients who underwent one of two radiation regimens: accelerated fractionation or conventional fractionation. They found that both the local control rate and survival were higher for the accelerated fractionation regimen, wherein the package treatment time was shorter by 2 weeks than for the conventional fractionation regimen. Therefore, in cases of delay in commencing PORT, accelerated fractionation schedules should diminish the damage. Rosenthal et al. [11] , in a retrospective study, investigated patients with a treatment package time of more or less than 100 days. The longer package was found to be detrimental to tumor control and survival. The authors concluded that it is not the reduction in the time gap between surgery and radiotherapy that is crucial to outcome, but rather limiting the whole treatment package time to less than 100 days.
Awwad et al. [20] analyzed the cell proliferation in locally advanced HNC in association with accelerated hyperfractionated (AHF) or conventional fractionation PORT schedules. They found that the best local control Commencing postoperative radiotherapy Marshak and Popovtzer 83 was achieved in the AHF arm when PORT was started within 6 weeks after surgery and when the OTT did not exceed 10 weeks. In the conventional fractionation arm, neither of these parameters -delay in PORT and prolongation of OTT -seemed to influence outcome. They therefore suggested that the duration of the OTT is more significant than the gap in starting PORT because of the accelerated repopulation process that occurs during PORT.
These results are also in accordance with the findings of the phase-III study of Sanguineti et al. [21 • ] wherein there was a trend of improved local control in patients with delayed PORT treated by AHF compared with patients with similar delay treated by conventional fractionation.
Combining chemotherapy with PORT
The MACH-NC group [22] performed a meta-analysis of randomized trials of locoregional radiation treatment with or without chemotherapy. The combined regimen yielded an absolute 8% 5-year survival benefit.
Bernier et al. [23] , in a phase-III trial (EORTC #2931), prospectively administered PORT with or without concomitant chemotherapy to patients with advanced HNC. They found that the combined approach improved local control by 13%, and 5-year survival by 11%. Interestingly, 32% of the patients in the chemoradiation group and 25% of the patients in the PORT-only group received treatment after a delay of more than 43 days; 21 started treatment after 8-10 weeks. There was no mention in the study that the delay influenced survival.
Conclusion
It remains uncertain if outcome is significantly reduced by a delay in commencing PORT in patients with advanced HNC tumors. The data accrued in the last 5 years indicate that the use of advanced treatment techniques such as altered fractionation, reduction of OTT, and combined PORT and chemotherapy may minimize any adverse effects of a delay.
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